Does Fatty15 Work? What the Human Trial Evidence Shows

Published human trials show that Fatty15 has only one randomized clinical study, where it lowered low-density lipoprotein cholesterol in eighty-eight women with fatty liver disease over twelve weeks. At Longevity Benchmark, we review published clinical trials to separate measurable biological responses from commercial marketing claims.

What the Human Evidence Actually Is

In one 12-week double-blind randomized controlled trial of 88 Chinese women with fatty liver disease, adding pentadecanoic acid to an Asian-adapted Mediterranean-style diet lowered low-density lipoprotein cholesterol further than diet alone and increased one beneficial gut bacterium. This study, known as the TANGO randomized controlled trial by Chooi and colleagues, was published in 2024 and registered as NCT05259475. It represents the only published randomized human trial evaluating supplemental C15:0.

The trial divided eighty-eight participants across three distinct arms: diet with C15:0 supplementation (thirty-one participants), diet without C15:0 (twenty-eight participants), and a control group maintaining their habitual diet without C15:0 (twenty-nine participants). Over twelve weeks, intention-to-treat weight loss was 4.0 ± 0.5 kilograms (5.3 percent) in the diet plus C15:0 group, 3.4 ± 0.5 kilograms (4.5 percent) in the diet alone group, and 1.5 ± 0.5 kilograms (2.1 percent) in the control group. Liver proton density fat fraction fell by 33 percent, 30 percent, and 10 percent across the three groups, respectively.

Both dietary groups outperformed the control group on body weight, liver fat, total cholesterol, gamma-glutamyl transferase, and triglycerides. Across all three groups, fat mass, visceral abdominal fat, subcutaneous abdominal fat, fasting insulin, glycated hemoglobin, and blood pressure dropped in parallel with weight loss. The Mediterranean-style diet performed the bulk of the metabolic improvement. The specific supplemental effect attributed to C15:0 was an incremental reduction in low-density lipoprotein cholesterol and an increased abundance of the gut microbe Bifidobacterium adolescentis.

The published abstract of the TANGO trial does not report the daily milligram dose of C15:0 administered to participants. Researchers cannot confirm whether the study used 100 milligrams or a different amount. The trial also never evaluated arterial plaque volume, clinical cardiovascular events, human longevity, cognitive function, sleep quality, or depressive symptoms.

What Is in the Capsule, and What It Costs

Fatty15 is a single-ingredient dietary supplement containing pure pentadecanoic acid, an odd-chain saturated fatty acid known chemically as C15:0. Each standard capsule supplies 100 milligrams of C15:0 in a small vegetable cellulose shell designed for once-daily consumption. Fatty15 states that the active ingredient is derived from plants and purified to greater than 99 percent purity. The product is manufactured in a facility that complies with current Good Manufacturing Practice regulations and undergoes inspection by the Food and Drug Administration (FDA).

Fatty15 states on its website that the formulation earned a TRUST score of 9.88 from the testing organization Suppco. This score is reported as a manufacturer claim, as an independent certificate of analysis was not published alongside the rating. Fatty15 also markets a practitioner-exclusive product named Advanced Formula Extra Strength, described as providing a higher dose. The exact milligram quantity of C15:0 in this practitioner formula is not published on accessible product pages.

Pricing information is entirely absent from the public pages of the Fatty15 website. When checked on 14 October 2026, the direct product purchase link at fatty15.com/products/fatty15 returned an HTTP 404 page-not-found error. The homepage notes that costs may be reimbursed through Health Savings Accounts and Flexible Spending Accounts, that the product works with major insurance providers, and that a cash pay option exists with shipping included. Because Fatty15 is intended for daily consumption, it represents an ongoing recurring expense. Prospective buyers must obtain the current subscription and single-purchase pricing directly from Fatty15 before enrolling in an automatic delivery plan.

The Claims, Against the Evidence

Marketing materials for Fatty15 list extensive physiological claims that extend well beyond the single published human clinical trial. Fatty15 claims that the supplement can slow and reverse cellular aging, strengthen cell membranes, protect against lipid peroxidation, and activate adenosine monophosphate-activated protein kinase and protein kinase B. The manufacturer also asserts that the fatty acid repairs mitochondria, supports glucose control, activates peroxisome proliferator-activated receptors alpha and delta to aid liver function, and inhibits more than eighteen proinflammatory cytokines.

Fatty15 additionally connects C15:0 to enhanced dopamine and endocannabinoid signaling, sharper cognitive health, deeper sleep, and protected red blood cell membranes against oxidative stress. To support subjective wellbeing claims, Fatty15 cites an internal customer survey of 6,243 buyers where 70 percent reported noticing benefits within sixteen weeks, citing improvements in sleep, energy, and mood. A commercial customer survey is not a controlled clinical trial: it lacks a placebo group, does not use randomization, lacks blinding, and records self-reported impressions from consumers who already decided to purchase the product.

A comparison of each claim against documented medical literature reveals a distinct gap between laboratory hypotheses and proven human outcomes. When shoppers learn how to read a supplement label, they discover that mechanistic cell studies rarely match complex clinical endpoints.

The Mouse Result Everyone Is Linking To

Recent viral interest in pentadecanoic acid stems from a preclinical laboratory study published in 2026. In that paper, titled 'A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice' and published in Nature, Yin and colleagues at Sun Yat-sen University and Shenzhen Bay Laboratory investigated vascular plaque formation. In male mice genetically prone to atherosclerosis fed a high-fat diet, pentadecanoic acid administered three times weekly for eight weeks cut arterial plaque by about half and lowered circulating cholesterol levels.

The investigators discovered that the human gut bacterium Bacteroides uniformis naturally produces pentadecanoic acid. When isolated, the fatty acid directly binds and inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, commonly called HMG-CoA reductase. This is the exact enzyme targeted by pharmaceutical statins. By inhibiting this enzyme, liver cells increase their production of low-density lipoprotein receptors, clearing cholesterol particles from the bloodstream.

These animal findings provide compelling biological insights, but they cannot be treated as evidence of human clinical efficacy. The experiment was conducted exclusively in male mice. Differences in human dietary patterns and individual gut microbial communities could alter or negate this response. Furthermore, co-author Xiangyu Mou disclosed a pending patent covering the use of pentadecanoic acid against atherosclerosis. Sharing an enzymatic target with a prescription drug does not mean a supplement shares its proven clinical trial record. Patients should never alter, reduce, or stop a prescribed statin based on rodent experiments. Our detailed analysis of the pentadecanoic acid gut microbe mouse study outlines the laboratory data in full.

The Result That Points the Other Way

As reported by the Nature news team and relayed by MedicalXpress on 14 October 2026, a 2026 analysis of two long-running human cohorts found no association between higher circulating blood levels of pentadecanoic acid and a lower incidence of cardiovascular disease. That points the opposite way to the idea that a higher level is protective.

These two results point in opposite directions. Cardiovascular specialist Ben Chen of Australia's Monash Victorian Heart Institute noted that 'the clinical evidence supporting a cardiovascular benefit remains limited'.

A short-term change in a blood marker is not the same evidence as a change in clinical events, and no published outcome data exists for C15:0 either way. A compound can produce a modest reduction in circulating cholesterol over twelve weeks without translating into fewer vascular occlusions over a lifetime. An accurate interpretation of pentadecanoic acid acknowledges both the positive laboratory mechanisms and the neutral human observational data.

Cheaper Equivalents, Dietary Sources, and the Omega-3 Question

Consumers frequently ask whether dietary sources or generic supplements provide a cheaper equivalent to Fatty15. Pentadecanoic acid is not a synthetic pharmaceutical; it is an odd-chain saturated fatty acid naturally present in whole foods, particularly dairy fat.

However, no published clinical trials have compared whole-food consumption against concentrated C15:0 capsules. Medical literature does not provide specific serving sizes of dairy fat that reliably deliver a targeted milligram dose of C15:0. The single-ingredient Fatty15 capsule offers a standardized, isolated intake of 100 milligrams without accompanying fats, but whether this isolation confers health advantages over a balanced diet remains untested.

Similarly, consumers often question whether Fatty15 can replace marine omega-3 fatty acids. Pentadecanoic acid is an odd-chain saturated fat, whereas eicosapentaenoic acid and docosahexaenoic acid are long-chain polyunsaturated fats. Marine omega-3s have undergone testing in extensive trials, as documented in our review of whether fish oil supplements work. No clinical trial has evaluated Fatty15 against marine fatty acids, and one cannot substitute for the other. Individuals tracking fatty acid status can assess their cellular levels using an Omega-3 Index blood test.

What Is Not Known About Safety

The published safety profile of supplemental pentadecanoic acid in humans remains sparse. Common consumer search queries ask whether Fatty15 causes constipation, diarrhea, heart palpitations, blood pressure spikes, unexpected weight gain, or pharmaceutical interactions. Published medical literature currently contains no data to confirm, quantify, or rule out any of these potential adverse effects.

The entire human clinical trial record consists of eighty-eight participants followed for twelve weeks in the TANGO trial. A study of this size and duration is statistically incapable of detecting rare adverse reactions, cumulative organ toxicity, or long-term safety signals. Fatty15 capsules display standard statutory disclaimers stating that the statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Potential drug interactions remain an open question. Because preclinical research indicates that pentadecanoic acid binds and inhibits HMG-CoA reductase, taking C15:0 alongside prescription lipid-lowering therapies like statins warrants clinical caution. Anyone currently prescribed medication for cardiovascular or metabolic conditions must discuss pentadecanoic acid with their prescribing doctor or pharmacist before starting a daily regimen.

What a Buyer Is Actually Purchasing Today

The purchase of Fatty15 represents a personal choice between funding early-stage biological exploration and waiting for rigorous clinical validation. A buyer today is purchasing a biological mechanism with one narrow human trial showing an LDL-cholesterol reduction. Preclinical rodent models cannot guarantee cardiovascular outcomes in human beings.

The product may appeal to experimental consumers who understand that they are testing an isolated fatty acid backed by a single twelve-week trial in eighty-eight women with fatty liver disease. Such buyers must recognize that broad claims regarding sleep, cellular rejuvenation, and mood rest primarily on customer surveys and in vitro experiments. Looking for third-party certifications, such as comparing NSF versus USP verification, helps identify brands that publish independent batch analyses.

Our assessment would shift if independent researchers publish randomized, placebo-controlled human trials demonstrating that supplemental C15:0 reduces cardiovascular events, slows arterial plaque accumulation, or improves hard metabolic endpoints in diverse populations. A clear, publicly accessible pricing model would also improve consumer transparency. Individuals concerned about vascular health can obtain an objective blood panel to assess the markers the one human trial moved, including apolipoprotein B levels and non-HDL cholesterol status, through a physician.

Related

• Pentadecanoic Acid Gut Microbe Artery Plaque Study in Mice
• Do Fish Oil Supplements Work? Clinical Trial Evidence
• Omega-3 Index Blood Test and Cellular Health
• How to Read a Supplement Label and Verify Ingredients
• Apolipoprotein B (ApoB) Testing and Cardiovascular Risk
• Urolithin A Evidence and Cellular Longevity Review